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Lipid bilayersfusion process of SARS-CoV virus, several regions of the S2 virus envelope
glycoprotein are necessary. Recent studies have identiﬁed three membrane-active regions in the S2 domain
of SARS-CoV glycoprotein, one situated downstream of the minimum furin cleavage, which is considered the
fusion peptide (SARSFP), an internal fusion peptide located immediately upstream of the HR1 region (SARSIFP)
and the pre-transmembrane domain (SARSPTM). We have explored the capacity of these selected membrane-
interacting regions of the S2 SARS-CoV fusion protein, alone or in equimolar mixtures, to insert into the
membrane as well as to perturb the dipole potential of the bilayer. We show that the three peptides interact
with lipid membranes depending on lipid composition and experiments using equimolar mixtures of these
peptides show that different segments of the protein may act in a synergistic way suggesting that several
membrane-active regions could participate in the fusion process of the SARS-CoV.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Coronaviruses are a diverse group of enveloped, positive-stranded
RNA viruses that cause respiratory and enteric diseases in humans
and other animals. Severe acute respiratory syndrome coronavirus
(SARS-CoV) is a newly emergent member in the family Coronaviridae
that cause a severe infectious respiratory disease. SARS-CoV is
distinct from previously characterized groups of coronaviruses [1,2],
and unlike other human coronaviruses whose infections are usually
very mild, SARS-CoV produced mortality rates as high as 10% but
increased to greater than 50% in persons older than age 60 [3]. At
present there is no vaccine available against any human coronavirus
infection, and although SARS-CoV has been successfully restrained,
re-emergence from animal reservoirs is still a potential risk for future
recurrences [4].
SARS-CoV infection, similarly to other envelope viruses, is achieved
through fusion of the lipid bilayer of the viral envelope with the hostdi-8-ANEPPS, 4-(2-(6-(Diocty-
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l rights reserved.cell membrane [5,6], although recent studies have shown that the
entry may be also pH-dependent [7]. The spike glycoprotein S is a
surface class I viral fusion glycoprotein that mediates viral entry by
binding to the cellular receptor and induces membrane fusion. The S1
subunit contains the receptor binding domain, whereas the S2 is
responsible for the fusion between the viral and cellular membranes
[2,8]. S2 contains two highly conserved heptad repeat regions (HR1
and HR2, see Fig. 1A) [9–11], similarly to other viral Class I fusion
proteins, including HIV-1 gp41, inﬂuenza hemagglutinin HA2, Ebola
virus glycoprotein and paramyxovirus F protein [12,13]. All of them
have been classiﬁed as Class I transmembrane glycoproteins and are
displayed on the surface of the viral membrane as oligomers. Class I
viral proteins also contain a hydrophobic region denominated as the
fusion peptide (FP) and other hydrophobic region immediately
adjacent to the membrane-spanning domain denominated as the
pre-transmembrane domain (PTM). Computer sequence predictions
and systematic amino acid mapping studies of the S2 domain have
located the HR1 region to amino acids approximately from 892 to 972,
while the HR2 region extends approximately from amino acids 1142 to
1184 [2,10,11,14–17]. Binding of the S1 subunit to the receptor is
thought to trigger a series of conformational changes in S2 that brings,
via the formation of an antiparallel heterotrimeric six-helix bundle by
the two HR regions, the putative fusion peptide and the transmem-
brane domain in close proximity. These structural rearrangements in
the S protein generate the energy that drives the fusion of the viral and
cellular lipid membrane.
Although it was initially believed that viral fusion glycoproteins
interacted with the membrane solely by means of the FP, different
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fusion to occur [18–24]. These membrane-interacting regions are
capable of modifying the biophysical properties of phospholipid
membranes, suggesting that several segments may have an important
role in the fusion process [18,25–31]. While much progress has been
made in understanding the implication of fusion peptides of inﬂuenza,
HIV and other viruses in fusion, available data concerning the fusion
peptide of coronaviruses, particularly in the case of SARS-CoV, are
scarce. It has been predicted that the sequence comprising residues
from 858 to 886 of the S2 domain of the SARS-CoV spike glycoprotein
is the FP domain since it has strong membrane-perturbing capacities
[14,32], and furthermore mutations in this region cause inhibition of
S-mediated cell fusion bymore than 70% [33]. However, recent studies
have shown that the region comprising residues 770 to 788 has a
much more potent fusogenic activity than the former sequence and
suggested to constitute the fusion peptide of the S2 glycoprotein [34].
The importance of PTM segments on the mechanism of viral entry has
also been demonstrated in the membrane fusion proteins of HIV, FIV,
Ebola virus, HSV and VSV through the use of site-directedmutagenesis
and the study of the interaction of synthetic peptides withmembranes
[24,35–43]. Similar observations suggest that the PTM domain of
SARS-CoV may also play an essential role in virus entry [32,44–46].
Upon triggering, the N-terminal fusion peptide region (comprised by
amino acid residues 770 to 788) might be the ﬁrst one to acquire the
competence to bind to and insert into the membrane, whereas the
region comprised by amino acids 858 to 886 (internal fusion peptide)
might be fundamental for subsequent steps of the fusion process
because it would become located adjacent to the transmembrane
domain after the necessary rearrangements that give rise to the
formation of the six-helix coiled-coil bundle [47].
Although much information has been obtained in recent years on
membrane fusion, we do not know yet the processes and the
mechanism behind it. Elucidating the nature of the interactions
between phospholipid and membrane proteins is essential for the
understanding of the structure and function of the implicated
molecules, clarifying the speciﬁc roles of speciﬁc types of phospho-
lipids in biological membranes. Based on our work [32,46,48] we have
selected three speciﬁc sequences from the SARS-CoV S2 sequence (Fig.
1), i.e., SARSFP, comprised by amino acid residues 770 to 788 and
corresponding to the putative fusion peptide of the protein, SARSIFP,
comprised by amino acid residues 873 to 888 and corresponding to
the suggested internal fusion peptide, and SARSPTM, comprised by
amino acid residues 1185 to 1202 and corresponding to the PTM
domain of the protein. Here, we explore the monolayer penetration of
these peptides, their capacity to insert into the membrane as well as
the perturbation of the dipole potential of the bilayer. Moreover, we
show through experiments using equimolar mixtures of these
peptides that they might be involved in the merging of the viral and
target cell membranes working synergistically in the native protein.Fig. 1. Schematic view of the organization of SARS-CoV spike glycoprotein S (amino acid res
regions: the predicted heptad repeat regions HR1 and HR2, the transmembrane domain (TM
fusion peptide (SARSFP), the internal fusion peptide (SARSIFP) and the pre-transmembrane d2. Materials and methods
2.1. Materials and reagents
Peptides pertaining to the S2 domain of SARS-CoV (770MWKTP-
TLKYFGGFNFSQIL788, SARSFP), (873GAALQIPFAMQMAYRF888, SARSIFP)
and (1185LGKYEQYIKWPWYVWLGF1202, SARSPTM) with N-terminal
acetylation and C-terminal amidation were obtained from Genemed
Synthesis (San Francisco, CA, USA). The SARSFP peptide has a Trp
residue replacing a Tyr one. This conservative substitution has no
effect in membrane perturbation and fusion assays as shown
elsewhere [34]. The peptides were puriﬁed by reverse-phase HPLC
(Vydac C-8 column, 250×4.6 mm, ﬂow rate 1 ml/min, solvent A, 0.1%
triﬂuoroacetic acid, solvent B, 99.9 acetonitrile and 0.1% triﬂuoroacetic
acid) to better than 95% purity, and its composition and molecular
mass were conﬁrmed by amino acid analysis and mass spectroscopy.
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), egg sphingomye-
lin (ESM) and cholesterol (CHOL) were obtained from Avanti Polar
Lipids (Alabaster, AL, USA). 4-(2-(6-(Dioctylamino)-2-naphthalenyl)
ethenyl)-1-(3-sulfopropyl)-pyridinium inner salt (di-8-ANEPPS) was
obtained fromMolecular Probes (Eugene, OR, USA). All other reagents
used were of analytical grade from Sigma-Aldrich (Madrid, ES, EUR).
Water was deonized, twice-distilled and passed through a Milli-Q
equipment (Millipore Ibérica, Madrid, ES, EUR) to a resistivity higher
than 18 MΩ cm.
2.2. Preparation of large unilamellar vesicles
Aliquots containing the appropriate amount of lipid in chloroform–
methanol (2:1 vol/vol) were placed in a test tube, the solvents were
removed by evaporation under a stream of O2-free nitrogen, and
ﬁnally, traces of solvents were eliminated under vacuum in the dark
for >3 h. The lipid ﬁlms were resuspended in buffer and incubated at
25 °C with intermittent vortexing for 30 min to hydrate the samples
and obtain multilamellar vesicles. The samples were frozen and
thawed ﬁve times to ensure complete homogenization with occa-
sional vortexing. Large unilamellar vesicles (LUV) with a mean
diameter of 0.1 μmwere prepared from multilamellar vesicles by the
extrusion method [49] using polycarbonate ﬁlters with a pore size of
0.1 μm (Nuclepore Corp., Cambridge, CA, USA). The phospholipid and
peptide concentration was measured by methods described pre-
viously [50,51].
2.3. Insertion of peptides into lipid monolayers
Insertion of peptides into lipid monolayers, residing on an air/
water interface, was measured using magnetically stirred circular
Teﬂon wells (Multiwell plate, subphase volume 3 mL, Kibron Inc.,idues 1 to 1255 for the full length), showing the approximate structural and functional
) and the relative position of the peptides used in this study which correspond to the
omain (SARSPTM). The sequences of the peptides are also shown.
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wire attached to a microbalance (DeltaPi, Kibron Inc., Helsinki, FIN,
EUR) interfaced to a computer. Lipids were mixed at the indicated
molar ratios in chloroform (approximately 1 mM) and then spread
onto the air-buffer interface (20mMHEPES, 0.1 mMEDTA, pH 7.4). The
lipid monolayers were allowed to equilibrate for approximately
15 min at different initial surface pressures (π0) before the injection
of the peptides into the subphase. The increment in π after peptide
addition was complete in approximately 30 min and the difference
between the initial surface pressure (π0) and the value observed after
the penetration of peptide into the ﬁlms was taken as Δπ. The data
shown represent the average from triplicate measurements and are
represented as Δπ vs. π0. These graphs yield the critical surface
pressure πc corresponding to the lipid lateral packing density
preventing the intercalation of the peptides into the lipid ﬁlms. All
measurements were performed at ambient temperature (≈25 °C).
2.4. Compression isotherms
A computer-controlled Langmuir type ﬁlm balance (μTrough XL,
Kibron Inc., Helsinki, FIN) equipped with a Precision Plus trough was
used to measure π-A isotherms, using the embedded features of the
control software (FilmWare 3.57, Kibron Inc., Helsinki, FIN, EUR). The
indicated lipid mixtures were made in chloroform and were spread
onto the air–aqueous phase interface (20 mM HEPES, 0.1 mM EDTA,
pH 7.4) with a microsyringe (Hamilton); mixtures of peptides were
added prior to lipid. The total surface area of the trough was 120 cm2
and the volume of the subphase was 35 ml. After 5 min equilibration
to ensure evaporation of the solvent, the ﬁlm compressionwas started
using two symmetrically moving barriers. Compression rate was 4 Å2/
chain/min, to allow for the reorientation and relaxation of the lipids in
the course of the compression. Surface pressure (π) was monitored
with a metal alloy probe hanging from a high precision microbalance
(KBN 315, Kibron Inc., Helsinki, FIN, EUR) connected to a computer.
Each run was repeated at least twice to ensure reproducibility.
2.5. Quenching of Trp emission by acrylamide
Peptides were added to a solution of LUVs and after 1 h of
equilibration, ﬂuorescence emission spectra were recorded in a SLM
Aminco 8000 spectroﬂuorometer with excitation and emission
wavelengths of 290 and 343 nm, respectively, and 4 nm spectral
bandwiths. Measurements were carried out in 20 mM HEPES, EDTA
0.1 mM, pH 7.4. Intensity values were corrected for dilution, and the
scatter contributionwas derived from lipid titration of a vesicle blank.
Aliquots of a 4 M solution of the water-soluble quencher acrylamide
were added to the peptide in the absence or the presence of the
liposomes. The lipid-to-peptide ratio was 100:1. The values obtained
were corrected for dilution, and the scatter contribution was derived
from acrylamide titration of a vesicle blank. The data were analyzed
according to the Stern–Volmer equation [52], F0 /F=1+Ksv [Q], where
F0 and F represent the ﬂuorescence intensities in the absence and the
presence of the quencher [Q], respectively, and Ksv is the Stern–
Volmer quenching constant.
2.6. Measurement of the membrane dipole potential
Aliquots containing the appropriate amount of lipid in chloro-
form–methanol (2:1 v/v) and di-8-ANEPPS were placed in a test tube
to obtain a probe/lipid molar ratio of 1/100 and LUVs with a mean
diameter of 0.1 μm were prepared as described previously. Steady-
state ﬂuorescence measurements were recorded with a Varian Cary
Eclipse spectroﬂuorimeter. Dual wavelength recordings with the dye
di-8-ANEPPS were obtained by exciting the samples at two different
wavelengths (450 and 520 nm) and measuring their intensity ratio, R
(450/520), at an emission wavelength of 620 nm [53,54]. This ratioreﬂects the changes in the total membrane dipole potential moment,
as they cause a shift in the excitation spectrum maximum of di-8-
ANEPPS. By exciting the membrane suspensions at two different
wavelengths corresponding to the maximum and the minimum of
the difference spectrum, a ﬂuorescence intensity ratio R can be
calculated, which can be used as a measure of the relative changes in
the magnitude of the dipole potential. The ﬂuorescence ratio R is
deﬁned as the ratio of the ﬂuorescence intensity at an excitation
wavelength of 450 nm divided by that at 520 nm. The lipid
concentration was 200 μM, and all experiments were performed at
room temperature.
3. Results
The SARS-CoV spike glycoprotein, classiﬁed as a Class I viral fusion
protein, consists of an extracellular domain, a transmembrane
domain, and an intracellular domain (Fig. 1). It is also known that
several regions of viral fusion proteins bind and interact with
membranes, experience conformational changes and interact
between each other, which make possible the fusion of the viral and
cell membranes [55,56]. From our previous work, we have selected
three speciﬁc sequences from the SARS-CoV S2 sequence, i.e., SARSFP,
SARSIFP and SARSPTM (S2 regions comprising residues from 770 to 788,
from 873 to 888, and from 1185 to 1202, see Fig. 1) to explore the
interaction of these peptides, either alone or in combination, with
monolayers or LUVS having different lipid compositions.
3.1. Penetration of SARS S2 derived peptides into lipid monolayers
The insertion of the SARS S2 derived peptides SARSFP, SARSIFP and
SARSPTM into lipid monolayers with different initial pressures π0 was
measured by observing the increment in surface pressure (Δπ)
following the addition of the peptides into the subphase (Fig. 2 and
Table 1). Interestingly, there was a different behavior of the different
peptides depending on the lipid composition of the monolayers.
Peptide SARSPTM is highly surface active and was intercalated
effectively in all four different lipidic compositions (Fig. 2A). However,
the overall charge of the lipid monolayer played a signiﬁcant role in
peptide insertion, since we observed an increase in πc from 35 mN/m
for POPC monolayers to 45 mN/m for POPC/POPG monolayers. The
presence of either ESM or CHOL reduced the intercalation of the
SARSPTM peptide, since πc decreased to 31 and 30 mN/m, respectively
in the presence of these lipids. In contrast to SARSPTM, the increment
in the surface pressure at low π0 was different for SARSFP (Fig. 2B).
Whereas the maximum Δπ varied between 25 and 31 mN/m for the
SARSPTM peptide, the values measured for the SARSFP peptide varied
between 15 and 21 mN/m, suggesting a more shallow location of the
latter peptide. The presence of a negatively-charged phospholipid
induced a similar effect as observed for SARSPTM, πc increasing from
32 mN/m to 41 mN/m. Similarly, the presence of either ESM or CHOL
reduced πc from 32 mN/m to about 25 mN/m (Table 1). In the case of
the SARSIFP peptide, the maximum Δπ values were similar to those
found for SARSFP, but the dependence of πc on monolayer composition
was very different (Fig. 2C). Interestingly, SARSIFP readily intercalated
into POPCmonolayers with a πc value of 40 mN/m, but the presence of
POPG diminished its insertion, displaying a πc value of approximately
26 mN/m. Interestingly, the presence of CHOL abolished completely
the insertion of the SARSIFP peptide, since the πc value observed was
about 16 mN/m. However, the presence of both ESM and CHOL
increased πc to 29 mN/m.
3.2. Penetration of SARS S2 derived peptides mixtures into lipid
monolayers
As it was commented previously, and in the context of the
membrane fusion mechanism elicited by SARS-CoV envelope
Fig. 2. Insertion into lipid monolayers of the S2 SARS-CoV derived peptides. The increment in the surface pressure (Δπ) of the lipid monolayer due to the addition of (A) SARSPTM, (B)
SARSFP, (C) SARSIFP, (D) an equimolar mixture of SARSFP and SARSPTM, (E) an equimolar mixture of SARSIFP and SARSFP and (F) an equimolar mixture of SARSPTM and SARSIFP into the
subphase as a function of the initial pressure (π0). The lipid compositions of the monolayers were POPC (●), POPC/POPG at a molar ratio of 7:3 (▲), POPC/ESM/CHOL at a molar ratio of
8:1:1 (■), POPC/CHOL at a molar ratio of 8:2 (□) and POPC/ESM at a molar ratio of 8:2 (Δ).
Table 1
Critical surface pressure πc values for monolayers having different lipid compositions in
the presence of the SARS derived peptides as indicated
Lipid composition
of the monolayers
SARSPTM SARSFP SARSIFP SARSFP
+SARSPTM
(1:1)
SARSFP
+SARSIFP
(1:1)
SARSIFP
+SARSPTM
(1:1)
Expa Exp Exp Exp Averb Exp Aver Exp Aver
POPC 35 32 40 40 33.5 36 36 32 37.5
POPC/POPG (7:3) 45 41 26 36 43 30 33.5 28 35.5
POPC/ESM/CHOL
(8:1:1)
31 25 29 35 28 43 27 40 30
POPC/CHOL (8:2) 30 24 16 32 27 26 20 28 23
POPC/ESM (8:2) – – – 38 – 36 – 35 -
a Exp, experimental values obtained through the analysis of the data presented in Fig. 2.
b Aver, average value obtained from the sum of the individual experimental values.
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domains may have an essential role in facilitating it. Moreover, after
the rearrangements of the protein to form the six-helix coiled-coil
bundle, some of them would be adjacent to each other and therefore
interact together. Consequently, we also analyzed the insertion of
equimolar combinations of the three former peptides in monolayers
having different compositions. The insertion of an equimolar
combination of SARSFP plus SARSPTM in monolayers of different
compositions is showed in Fig. 2D. As expected, the increment in
surface pressure at low π0 was centered between the maxima
observed with both peptides alone. However, depending on lipid
composition some differences were observed compared to the data
shown above using single peptides. For POPC monolayers, πc was
40 mN/m, in contrast with a predicted value of about 33 mN/m,
when assuming an independent effect for each of the peptides (Table
1). In the case of the mixture POPC/POPG, the experimental πc was
36 mN/m, signiﬁcantly lower than the predicted one of about
43 mN/m. In the presence of mixtures containing ESM or CHOL, the
πc values were slightly decreased when compared with pure POPC
(35 mN/m and 32 mN/m, respectively). The mixture containing ESM
alone did yield a πc of about 38 mN/m, i.e., in between POPC and
POPC/ESM/CHOL (Table 1). The insertion into monolayers of an
equimolar combination of SARSFP plus SARSIFP is shown in Fig. 2D.
The πc values in POPC and POPC/POPG monolayers were similar to
the predicted ones, i.e., 36 mN/m and 30 mN/m (Table 1). The
inclusion of CHOL in POPC gave place to a πc value of 26 mN/m,
greater than the predicted one. However, the inclusion of ESM inPOPC did not induce any difference in πc when compared with pure
POPC. However, the inclusion of both ESM and CHOL promoted a
strong increase in πc (43 mN/m). In this case, the Δπ value at low π0
was less pronounced than that observed in the other lipids
suggesting a shallow penetration of the peptides in the monolayer.
The insertion of an equimolar combination of SARSPTM plus SARSIFP
in monolayers is showed in Fig. 2F (see Table 1). In POPC and POPC/
POPG monolayers, the πc values were lower than the predicted ones
(32 mN/m and 28 mN/m, respectively). However, the presence of
either ESM or CHOL to POPC gave place to πc values signiﬁcantly
increased if compared with the predicted ones (40 mN/M, 28 mN/M
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respectively).
3.3. Changes in the membrane potential by SARS S2 derived peptides
Changes in the membrane dipole potential elicited by SARS S2
derived peptides and their combinations were monitored bymeans of
the spectral shift of the ﬂuorescence probe di-8-ANEPPS [53]. The
variation of the ﬂuorescence intensity ratio R450/520 normalized as a
function of the peptide concentration for different membrane
compositions is shown in Fig. 3. In the presence of the SARSPTM
peptide a great decrease in the R450/520 value was measured in the
presence of the three mixtures tested, being slightly higher in the
presence of POPC/POPG than in the POPC and POPC/ESM/CHOL
samples (Fig. 3A). In contrast to the former peptide, SARSIFP had no
signiﬁcant effect on the membrane dipole potential (Fig. 3B),
suggesting that this peptide, despite being inserted in monolayers, is
not able to insert sufﬁciently in order to perturb the membrane
potential, or inserts in a way causing minimal alteration in the dipole
potential. For SARSFP, the change of dipole potential is less pronounced
than that caused by SARSPTM (Fig. 3C), suggesting a shallow position of
SARSFP in the membrane, in accordance with the monolayer data
shown above. However, the dependence on lipid composition is
signiﬁcantly more pronounced than seen for SARSPTM. In the presence
of membranes composed of POPC/POPG, the membrane potential
underwent a strong perturbation by the peptide, whereas for pure
POPC was smaller and quite insigniﬁcant in the case of POPC/ESM/
CHOL (Fig. 3C).Fig. 3. Effect of (A) SARSPTM, (B) SARSIFP, (C) SARSFP, (D) an equimolar mixture of SARSFP and S
SARSPTM and SARSIFP on themembrane dipole potential monitored through the ﬂuorescence r
lipid-to-peptide molar ratios. The lipid compositions were POPC (●), POPC/POPG at a molar
summing the single peptide experimental values are indicated by empty symbols and dash3.4. Changes in the membrane potential by SARS S2 derived peptides
mixtures
In a similar way as before, we carried out experiments with
equimolar mixtures of the three peptides. The combination of SARSFP
plus SARSPTM showed a change in membrane dipole potential similar
to the sum of the effects produced by the peptides alone, supposing an
independent and additive effect of each one of the peptides, with the
exception of the POPC/ESM/CHOL sample, where the experimental
value is greater than the expected linear sum (Fig. 3D). For themixture
of the SARSFP and SARSIFP peptides, a slight decrease of R is seen for all
the samples (Fig. 3E). Finally, we analyzed the effect of an equimolar
mixture of SARSIFP and SARSPTM on the membrane dipole potential as
shown in Fig. 3F. In this case, the decrease in the R value was
signiﬁcant, taking into account that SARSPTM but not SARSIFP had a
signiﬁcant effect on the dipole potential of the different membranes
tested. Therefore, a cooperative effect between SARSPTM and SARSIFP
can be inferred from the data.
3.5. Quenching of SARS S2 derived peptides by acrylamide
We also studied the accessibility of the Trp residues of the
peptides, either alone or in an equimolar combination, to collisional
quenching by acrylamide, a neutral, water-soluble, highly efﬁcient
quencher, which is unable to penetrate into the hydrophobic core of
the lipid bilayer. The quenching data are presented in Fig. 4 and the
Stern–Volmer quenching constants shown in Table 2. The linear
Stern–Volmer plots with a unitary intercept indicate that the TrpARSPTM, (E) an equimolar mixture of SARSIFP and SARSFP and (F) an equimolar mixture of
atio (R) of di-8ANEPPS labelled LUVs containing different lipid compositions at different
ratio of 7:3 (▲) and POPC/ESM/CHOL at a molar ratio of 8:1:1 (■). Values obtained by
ed lines.
Fig. 4. Stern–Volmer plots of the quenching of the Trp ﬂuorescence emission of (A) SARSPTM, (B) SARSFP, (C) an equimolar mixture of SARSFP and SARSPTM, (D) an equimolar mixture of
SARSIFP and SARSFP and (E) an equimolar mixture of SARSPTM and SARSIFP by acrylamide in aqueous buffer (○) and in the presence of liposomes composed of POPC (●), POPC/POPG at
a molar ratio of 7:3 (▲) and POPC/ESM/CHOL at a molar ratio of 8:1:1 (■). The lipid-to-peptide ratio was 100:1. The ﬁttings to the Stern–Volmer equation are also shown.
Table 2
Acrylamide Stern–Volmer quenching constant (KSV/M−1) for the SARS derived peptides
in buffer and in the presence of LUVs of different compositions
LUV composition SARSPTM SARSFP SARSFP+
SARSPTM (1:1)
SARSIFP+
ARSFP (1:1)
SARSIFP+
SARSPTM (1:1)
POPC 3.3 6.9 3.9 4.9 3.4
POPC/POPG
(7:3)
3.9 3.2 3.5 3.2 3.7
POPC/ESM/CHOL
(8:1:1)
3.4 6.8 3.6 6.9 2.5
Buffer 8.8 10.3 6.9 9.1 8.7
The lipid-to-peptide ratio was 100:1.
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quenching showed an acrylamide dependent concentration behavior,
so that the Stern–Volmer dynamic quenching formalism describes
accurately the data. It is necessary to mention here that the SARSPTM
peptide has three Trp residues, and the SARSFP peptide has a Trp
residue. SARSIFP was used in its wild type form, i.e., without Trp
residues, because it is only necessary for one peptide in the mixture to
obtain relevant ﬂuorescence data. The quenching data for the SARSPTM
peptide is presented in Fig. 4A and the resultant Stern–Volmer plots
reveal that in aqueous solution the Trp residues were highly exposed
to the solvent that led to a more efﬁcient quenching. However, in the
presence of model membranes, the extent of quenching was
signiﬁcantly reduced, indicating a poor accessibility of the Trp
residues to the aqueous phase, consistent with the incorporation of
the SARSPTM peptide into the lipid bilayer. Interestingly, the KSV values
were similar showing no preference for any one of the lipid
compositions used (Table 2). In contrast, and in the presence of
SARSFP, different KSV values were measured, being lowest for the
POPC/POPG liposomes (Fig. 4B). These data indicate that the Trp of the
SARSFP peptide is less exposed to the aqueous solvent in the presence
of membranes containing negatively-charged phospholipids than the
other mixtures (Table 2), in accordance with the monolayer and
membrane potential experiments shown above.
3.6. Quenching of SARS S2 derived peptides mixtures by acrylamide
The Stern–Volmer plots for the quenching of Trp in samples
containing equimolar mixtures of SARSFP and SARSPTM are shown inFig. 4C. The KSV values in the presence of all types of membranes were
lower than in solution, indicating that the peptide mixture was
effectively incorporated into the membranes, showing no preference
for any one of them. Signiﬁcantly, and comparing the KSV values in
solution (Table 2), the single peptides showed larger values than the
equimolar mixture (8.8 M−1 and 10.2 M−1 for SARSPTM and SARSFP,
respectively, and 6.9 M−1 for the equimolar mixture of SARSPTM and
SARSFP), suggesting the existence of a direct peptide–peptide interac-
tion in solution. For the equimolar mixture of the SARSFP and SARSIFP
peptides (Fig. 4D), although lower KSV values were obtained in the
presence of membranes than in solution, the lowest was observed for
the POPC/POPG sample (Table 2). These data would indicate that the
preference of SARSFP for negatively-charged phospholipids would
dominate in the mixture. The solution KSV value of the SARSFP and
SARSIFP mixture is slightly lower than that found for SARSFP,
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than that found for the former mixture. In the case of the equimolar
mixture of SARSPTM and SARSIFP, the KSV values obtained in the
presence of POPC and POPC/POCG mixtures were similar but higher
than that found for the mixture containing POPC/ESM/CHOL (Table 2).
The KSV value obtained for the mixture in solution was similar to that
found for SARSPTM, suggesting that there was no interaction between
these two peptides.
3.7. Compression isotherms of SARS S2 derived peptide mixtures
To further explore the interaction of SARS derived peptides we
recorded compression isotherms of pure POPC and a mixture of POPC/
ESM/CHOL at a lipid molar ratio of 8:1:1 in the presence of equimolar
mixtures of the SARS-CoV derived peptides (Fig. 5). As observed in the
π-A isotherms, the presence of all the peptide combinations caused a
signiﬁcant increase in the molecular area of the phospholipid
monolayer, indicating that the peptides are also occupying a fraction
of the interface. All the three combinations were squeezed-out from
the interface at a similar surface pressure, i.e., about 43–48 mN/m, as
shown by the convergence of the lipid/peptide isotherms with the
isotherm of the pure lipid sample. It can be also observed that the
peptide interaction with the POPC/ESM/CHOL mixture is more
efﬁcient since they cause a larger increase of the surface area perFig. 5. Compression isotherms for monolayers composed of (A) POPC and (B) POPC/
ESM/CHOL at a molar ratio of 8:1:1 in the absence (\) and in the presence of an
equimolar mixture of SARSFP and SARSPTM (·−·−·), an equimolar mixture of SARSIFP and
SARSFP (−−−) and an equimolar mixture of SARSPTM and SARSIFP (·····). The lipid-to-
peptide ratio was approximately 5:1.molecule. For example, at a surface pressure of 10 mN/m, ΔA, the
difference in area per molecule in the absence and in the presence of
the peptides, was 24.4, 29 and 32.8Å2 per molecule in POPC
monolayers but it increased to 30.8, 38.7 and 44.4 Å2 per lipid
molecule in POPC/ESM/CHOL monolayers for the equimolar mixtures
of SARSIFP + SARSPTM, SARSIFP + SARSFP and SARSPTM + SARSFP,
respectively.
4. Discussion
Enveloped viruses use membrane fusion proteins in order to
juxtapose and merge the viral and cellular membranes causing
membrane fusion. The viral fusion protein of SARS-CoV is the
envelope Spike glycoprotein and the domain responsible of the
fusion is the S2 domain. Until recently, it has been thought that the
N-terminal fusion peptide was the main region interacting with and
inserting into the target cell membrane inducing fusion of the lipid
bilayers. However, recent studies point to the fact that there are
several regions within Class I and Class II membrane fusion proteins
which are involved in the interaction with the membrane to
accomplish the fusion process [20,25,26,57]. Although in other Class
I fusion proteins plentiful data have been obtained to understand the
implication of these membrane-interacting segments in the fusion
mechanism, available information concerning the possible mem-
brane-active regions in coronavirus, and particularly in the case of
SARS-CoV, is scarce. Recent studies have identiﬁed three membrano-
tropic regions in the S2 domain of SARS-CoV S glycoprotein, one
situated downstream of the minimum furin cleavage, which is
considered the fusion peptide (SARSFP), an internal putative fusion
peptide helper for the fusion peptide located immediately upstream
of the HR1 region (SARSIFP) and the pre-transmembrane domain
(SARSPTM) [32,34,45,46,48]. To test the hypothesis that these regions
of the S2 protein may cooperatively interact in the native protein to
create a fusion pore or destabilize the membrane, we have analyzed
the monolayer insertion, change in membrane potential, peptide
accessibility and compression isotherms of equimolar mixtures of the
three synthetic peptides mentioned above. We report that synthetic
peptides corresponding to these three membrane-interacting seg-
ments might interact with and insert into the bilayer as well as they
can interact between them.
The three different peptides interact with lipid membranes
depending on the lipid composition, as it is shown in the monolayer
insertion and membrane dipole potential experiments. SARSPTM and
SARSFP peptides insert into lipid monolayers and their intercalation is
enhanced by the presence of the negatively-charged phospholipid,
POPG. Moreover, inclusion of CHOL to the lipid monolayer decreases
the SARSFP and SARSPTM intercalation into lipid monolayers. Never-
theless, SARSPTM had a different behavior to SARSFP decreasing the
dipole membrane potential. Whereas the change in the membrane
potential was nearly independent of phospholipid composition for
SARSPTM, the dependence on negatively-charged phospholipids is
stronger in the SARSFP peptide since the decrease in the dipole
potential of the membrane was more noticeable in POPG containing
LUVs. Furthermore, addition of ESM and CHOL reduces even more the
change in membrane potential caused by SARSFP. SARSIFP has also a
different behavior depending on lipid composition. SARSIFP penetrates
more easily into POPC than into POPG and CHOL containing
monolayers. However, the presence of both CHOL and ESM abolished
completely the intercalation of the peptide into the monolayer. In the
case of the peptide equimolar mixtures, we can observe that the
presence of both ESM and CHOL, components which mimic lipidic
rafts, induce a greater insertion, particularly in the case of SARSPTM
plus SARSIFP and SARSIFP plus SARSFP mixtures. A similar effect is
observed in the membrane dipole potential measurements. However,
the cooperation of SARSPTM and SARSIFP to change the membrane
potential occurs in all phospholipidic mixtures but the synergistic
Fig. 6. Hypothetical model of SARS-CoV fusion based on available data [32,34,45–47].
(A) The FP (yellow) inserts into the host cell, it is followed by the formation of the pre-
hairpin intermediate, and the core formed by the HR1 (orange) and HR2 (green) is
refolded into the six-helix bundle. (B) Subsequently hemifusion is induced, this process
being facilitated by the juxtaposition of the IFP (blue) and PTM (red) domains. These
two regions could also facilitate the formation of the fusion pore through lipid
destabilization in the late steps of the membrane fusion process, (C) leading to the
complete fusion.
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lipidic rafts.
Analysis of the ﬂuorescence data is more complicated because, in
this case, we were not able to detect any effect of the mixture in the
membrane and it is the ﬂuorescence of the peptide/s containing
tryptophans which allow us to infer the interaction with the
membrane. Despite this fact it is possible to obtain information of
these experiments. For the SARSPTM and SARSFP equimolar mixture,
similar low KSV values were observed in the three different LUV
compositions used despite the strong dependence on negative
charged phospholipids observed for SARSFP alone. So, SARSFP in
combination with SARSPTM, might insert deeper into the membrane.
However, it cannot be discarded that ﬂuorescence of SARSPTM
predominate in the mixture owing to its higher quantum yield.
Lower KSV values for the mixture SARSPTM and SARSIFP compared with
those observed for the single peptides indicate a signiﬁcant interac-
tion between the peptides in solution. In the SARSFP plus SARSIFP
mixture, the lower KSV is observed in POPG, similarly to what was
observed in SARSFP alone, so that SARSIFP does not seem to affect the
accessibility of SARSFP. Some type of interaction between SARSFP and
SARSIFP is possible since the KSV value is lower for the peptide mixture
than for SARSFP alone, but not in the same extent that SARSPTM and
SARSIFP. Lastly, although the KSV values for the SARSPTM and SARSIFP
mixture are similar to those observed for the SARSPTM, in the case of
LUVs mimicking rafts the KSV is signiﬁcant lower, which would
indicate a synergistic action of these peptides in order to perturb and
insert into this type of membrane.
The three peptides have positive net charges, +1 for SARSPTM and
SARSIFP and +2 for SARSFP. So, it would be expected a similar inﬂuence
of negatively-charged phospholipids on the membrane interaction of
the peptides. However, this is not the case and different results are
obtained suggesting that not only charge but hydrophobic interac-
tions are taking place and giving place to the differences found.
Taking into account the above mentioned experiments as well as
previously published data [46], SARSPTM interaction with the
membrane is not signiﬁcantly dependent on the presence of
negatively-charged phospholipids, in contrast to SARSFP [48]; how-
ever, both peptides would be embedded deeply into the membrane.
SARSIFP is also able to bind membranes but it would be located in a
shallow position at the membrane surface, perhaps prevented from
inserting by the presence of negatively-charged phospholipids.
Moreover, we have shown the existence of direct peptide–peptide
interactions in solution between the SARSPTM and SARSFP peptides.
Although it should be taken into account that the synergism we have
found might be different in the intact protein or might even not exist,
the experimental data described in this work would point to a
possible interaction in the pre-fusion state, as it has been already
shown in the case of HIV [58,59]. In this last case, it has been reported
the formation of a complex between similar domains in the gp41 pre-
fusion state acting as a kinetic trap to halt fusion. There is also ample
data suggesting that in the case of HIV membrane fusion starts before
the collapse of the six-helix bundle [60]. The mechanism of SARS
seems to be similar in some aspects and it might behave in the same
way. In Fig. 6 we present a hypothetical model of SARS-CoV fusion
based on available data [32,34,45–47]. In this model, the FP would
insert into the host cell, it would be followed by the formation of the
pre-hairpin intermediate, and afterwards the core formed by the HR1
and HR2 would be refolded into the six-helix bundle. Subsequently
hemifusion would be induced, this process being facilitated by the
juxtaposition of the IFP and PTM domains. These two regions could
also facilitate the formation of the fusion pore through lipid
destabilization in the late steps of the membrane fusion process.
The interaction between the IFP and the PTM would be one of the
most important steps of this process.
It has been suggested that other class I fusion proteins might
utilize similar motifs to hide and control the membrane-activesequences within metastable structures. In this way, in SARS-CoV,
SARSPTM and SARSFP might be forming a complex in the pre-fusion
state: just after exposing the fusion peptide and its insertion into the
host membrane, the formation of the six-helix bundle would bring
into close proximity the region immediately upstream of HR1
(SARSIFP) and the pre-transmembrane domain (SARSPTM). They
would ﬁnd the appropriate platform in the existent lipid rafts to
facilitate their interaction, and therefore facilitating the membrane
fusion process. Lipid rafts are functional membrane microdomains
where sphingolipids, cholesterol and associated proteins are
enriched. They have been shown to play a crucial role in many
biological events requiring the integrity of raft microdomains [61,62].
In addition, many viruses often use lipid rafts as a site for entry,
assembly and budding. Lipid rafts have been reported to be
implicated in the entry process of HIV [63], Semliki Forest virus
[64] and simian virus 40 [65]. In the case of coronavirus, there also
some evidence that lipid rafts are involved in virus entry [66,67].
Recent studies have reported that lipid rafts are involved in SARS-CoV
entry into cells, although it is not clear if ACE2 directly localize in rafts
or not. Therefore, it has been proposed that some unknown factors
involved in virus entry may localize to lipid rafts [7]. In the present
work, we have showed that some regions of the SARS-CoV S2
glycoprotein, mainly SARSPTM and SARSIFP, can have a different
interaction with lipid rafts. Consequently, lipid rafts might serve as a
platform for several regions in native spike glycoprotein to interact
and facilitate the membrane fusion process. In this way, lipid rafts
induce and modulate the joining of components of the membrane
2773J. Guillén et al. / Biochimica et Biophysica Acta 1778 (2008) 2765–2774docking and fusion machinery making possible their intermolecular
interactions by proximity [68,69].
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